Early detection of heart failure set for expansion with Ultromics receiving $55M in funding for large-scale operations
In a significant breakthrough for cardiology, Ultromics, a leading company specializing in AI-driven diagnostic solutions, has announced the successful establishment of Medicare reimbursement for both outpatient and inpatient use of its EchoGo platform. This development marks a strong foundation for the scaled adoption of EchoGo across hospitals in the United States.
The FDA-cleared EchoGo® platform is making waves in the cardiology field by significantly improving the detection of Heart Failure with Preserved Ejection Fraction (HFpEF) and cardiac amyloidosis. By analyzing standard echocardiograms with advanced deep learning algorithms, EchoGo extracts subtle disease signals that traditional methods often miss, enabling earlier and more accurate diagnoses without disrupting existing workflows or requiring new hardware.
Key improvements include a 73.6% enhancement in HFpEF detection compared to standard clinical risk scores, achieved by identifying hidden indicators of disease. In distinguishing cardiac amyloidosis from similar heart conditions, EchoGo Amyloidosis demonstrated 85% sensitivity and 93% specificity in a large multi-center study.
The scalability and integration of this AI solution are commendable, as it fits seamlessly into existing clinical workflows and is fully reimbursed under Medicare, supporting wide-scale deployment across hospitals and clinics in the U.S. Additionally, EchoGo was trained on one of the largest real-world echocardiogram datasets, and its diagnostic utility has been validated internationally, strengthening confidence in its diagnostic potential.
These AI-based tools address a major diagnostic blind spot where up to 64% of HFpEF cases remain undiagnosed. By facilitating earlier intervention, they potentially improve patient outcomes in complex heart failure cases that are traditionally difficult to detect with standard imaging and clinical tests.
In 2025, Ultromics launched EchoGo Score, a new feature that adds AI-driven probability scoring to EchoGo Heart Failure. The company has also received continued support from Oxford Science Enterprises, GV, Blue Venture Fund, and Oxford University. Victor Westerlind, Managing Director at Allegis Capital, stated that Ultromics is closing a long-standing blind spot in cardiology by making it easier for physicians to identify high-risk patients earlier.
Ultromics aims to expand across the U.S. and other key markets to bring AI-enhanced diagnostics to hospitals and echo labs with high volumes of at-risk patients. The company received $55 million through its Series C funding round, co-led by L&G, Allegis Capital, and Lightrock. Major US health systems, such as University of Chicago Medicine and UPMC Enterprises, also participated in the round.
In summary, AI-driven platforms like EchoGo are revolutionizing cardiology by leveraging routine echocardiograms with sophisticated image analysis and predictive modeling, making diagnosis faster, more accurate, and more accessible in routine clinical cardiac care.
- The digital health solution, EchoGo platform by Ultromics, is leveraging artificial intelligence to improve cardiovascular health by detecting Heart Failure with Preserved Ejection Fraction (HFpEF) and cardiac amyloidosis with higher accuracy, compared to traditional methods.
- In the realm of health-and-wellness, EchoGo's success in obtaining Medicare reimbursement for both outpatient and inpatient use paves the way for its wide-scale deployment, integrating seamlessly into existing clinical workflows and supporting early intervention in heart conditions.
- The scalable and technology-driven EchoGo platform, with its deep learning algorithms and large real-world echocardiogram dataset, is transforming cardiological science by closing a long-standing diagnostic blind spot, ultimately improving patient outcomes in complex medical-conditions associated with heart failure.
